摘要:
We describe a method of identifying a molecule suitable for the treatment, prophylaxis or alleviation of a Gpr100 associated disease, in particular diabetes and obesity, the method comprising determining whether a candidate molecule is an agonist or antagonist of Gpr100 polypeptide, in which the Gpr100 polypeptide comprises the amino acid sequence shown in SEQ ID NO: 3 or SEQ ID NO: 5, or a sequence which is at least 90% identical thereto.
摘要翻译:我们描述了鉴定适合于治疗,预防或减轻Gpr100相关疾病,特别是糖尿病和肥胖症的分子的方法,该方法包括确定候选分子是否是Gpr100多肽的激动剂或拮抗剂,其中Gpr100多肽 包含SEQ ID NO:3或SEQ ID NO:5所示的氨基酸序列,或与其至少90%相同的序列。
摘要:
In some embodiments, multilayer structures are electrochemically fabricated from at least one structural material (e.g. nickel), at least one sacrificial material (e.g. copper), and at least one sealing material (e.g. solder). In some embodiments, the layered structure is made to have a desired configuration which is at least partially and immediately surrounded by sacrificial material which is in turn surrounded almost entirely by structural material. The surrounding structural material includes openings in the surface through which etchant can attack and remove trapped sacrificial material found within. Sealing material is located near the openings. After removal of the sacrificial material, the box is evacuated or filled with a desired gas or liquid. Thereafter, the sealing material is made to flow, seal the openings, and resolidify. In other embodiments, a post-layer formation lid or other enclosure completing structure is added.
摘要:
Provided are Kv9.2 polypeptides comprising the amino acid sequence shown in SEQ ID NO. 3 or SEQ ID NO: 5, and homologues, variants and derivatives thereof. Nucleic acids capable of encoding Kv9.2 polypeptide are also disclosed, in particular, those comprising the nucleic acid sequences shown in SEQ ID No. 1, SEQ ID No.2 or SEQ ID NO: 4. Methods of identifying Kv9.2 agonists and antagonists are also provided.
摘要翻译:提供了包含SEQ ID NO:1所示氨基酸序列的Kv9.2多肽。 3或SEQ ID NO:5,及其同源物,变体和衍生物。 还公开了能够编码Kv9.2多肽的核酸,特别是包含SEQ ID No.1,SEQ ID No.2或SEQ ID NO:4所示的核酸序列的核酸。鉴定Kv9.2激动剂和 还提供拮抗剂。
摘要:
In some embodiments, multilayer structures are electrochemically fabricated from at least one structural material (e.g. nickel), at least one sacrificial material (e.g. copper), and at least one sealing material (e.g. solder). In some embodiments, the layered structure is made to have a desired configuration which is at least partially and immediately surrounded by sacrificial material which is in turn surrounded almost entirely by structural material. The surrounding structural material includes openings in the surface through which etchant can attack and remove trapped sacrificial material found within. Sealing material is located near the openings. After removal of the sacrificial material, the box is evacuated or filled with a desired gas or liquid. Thereafter, the sealing material is made to flow, seal the openings, and resolidify. In other embodiments, a post-layer formation lid or other enclosure completing structure is added.
摘要:
The invention provides a mixed heteroatomic ligand for an oligomerisation of olefins catalyst, which ligand includes at least three heteroatoms, of which at least one heteroatom is nitrogen and at least two heteroatoms are not the same. The invention also provides a multidentate mixed heroatomic ligand for an oligomerisation of olefins catalyst, which ligand includes at least three heteroatoms. At least one heteroatom may be nitrogen and at least 2 heteroatoms may not be the same.
摘要:
There are disclosed compounds of the formula (I): ##STR1## in which the variables R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, and X are defined in the specification. The compounds are useful as pharmaceuticals, especially as anti-inflammatory agents.
摘要:
Phenylethylamine derivatives of the formula ##STR1## wherein D.sub.1 represents a phenylethyl radical which is substituted with hydroxy and/or alkyl groups,R.sub.1 and R.sub.2 are hydrogen or alkyl,D.sub.2 represents hydrogen, an alkyl, or aryl group, and n is an integer from 3 to 5.These compounds are useful as pharmaceuticals, e.g., for treatment of cardiovascular conditions.
摘要:
Compounds of the formula, ##STR1## in which one of R.sub.30 and R.sub.40 represents a substituted phenylalkyl group and the other of R.sub.30 and R.sub.40 represents hydrogen or halogen, and R.sub.50 and R.sub.60 each independently represent hydrogen or alkyl.The compounds of the invention are useful for the treatment or prophylaxis of renal failure or cardiovascular disease.
摘要:
A handlebar assembly incorporates an apparatus for portable radio reception into a right and left bulbous housing element, one of which may house the portable radio apparatus and both of which house speaker devices. The bulbous housing elements serve as handgrips on a set of handlebars, such as those on bicycles and have disposed on the upper surfaces thereof, speaker grilles for the emitting of sound therefrom with at least one of the bulbous housing elements containing control members for switching and tuning of the portable radio apparatus.
摘要:
There are provided compounds of formula I, ##STR1## in which R.sub.1 represents OH,R.sub.2 and R.sub.3, which may be the same or different, each independently represent hydrogen, fluorine, chlorine, bromine, alkyl C1 to 6, nitro, nitrile, (CH.sub.2).sub.p R.sub.9 or SR.sub.9,W represents a single bond, a 1,2; 1,3; or 1,4-disubstituted benzene ring; a --CH.dbd.CH--group or a 1,4-cyclohexanediyl group;X respresents NH, O, S, SO.sub.2, CO, CH.sub.2, CONH or --COO;Y represents (CH.sub.2)q, CO, CS, SO.sub.2 and R.sub.20 represents hydrogen,or Y represents CR.sub.15 R.sub.16 CR.sub.17 R.sub.18,wherein the carbon atom bearing R.sub.15 and R.sub.16 is adjacent to X and in whichR.sub.15 and R.sub.18, together with the carbon atom to which they are attached form a carbonyl group, and R.sub.15, R.sub.16 and R.sub.20 each represent hydrogen, orR.sub.15 and R.sub.20 together form a chain --CH.sub.2 --, and R.sub.16, R.sub.17 and R.sub.18 each represent hydrogen, orR.sub.15, R.sub.16, R.sub.17 and R.sub.18 each independently represent hydrogen or alkyl C1 to 6 and R.sub.20 represents hydrogen;Z represents a single bond, NR.sub.19, CH.sub.2, O, CO, S or SO.sub.2,in which R.sub.19 represents hydrogen or alkyl C1 to 6;n, and m each independently represent an integer from 1 to 4 inclusive;q represents an integer from 1 to 3 inclusive;p represents 0 or an integer from 1 to 3 inclusive;R.sub.9 represents phenyl or phenyl substituted by hydroxy, andR.sub.10 represents hydrogen or chlorine, provided that(i) when R.sub.1 represents --OH, R.sub.2 and R.sub.3 both represent hydrogen,X represents NH, Y represents (CH.sub.2).sub.q, Z represents a single bond and R.sub.20 represents hydrogen,W does not represent a single bond;(ii) when R.sub.1 represents --OH, R.sub.2 and R.sub.3 both represent hydrogen, W represents a single bond,X represents NH and Z represents a single bond, thenat least one of R.sub.15, R.sub.16, R.sub.17 and R.sub.18 is alkyl C1 to 6;(iii) when X represents SO.sub.2, CO, COO or CONH, then Y does not represent CO, CS or SO.sub.2 ;(iv) when Y represents CO, CS or SO.sub.2, then Z does not represent CO or SO.sub.2,and pharmaceutically acceptable derivatives thereof.There are also described the use of the compounds of formula I as pharmaceuticals, methods for making the compounds and pharmaceutical, e.g. cardiac, compositions containing the compounds.